Originally posted by ASX News
- Release Date: 30/10/18 08:49
- Summary: Appendix 4C - quarterly
- Price Sensitive: Yes
- View Document
My very reliable sources tell me it was an American Broker that was partly responsible for the large buying the other day.
From the published research it seems like both flu tests and troponin tests will include ADO technology, and this will lead to significant revenue, especially in the medium term (I am in the health care field currently and both are signifcant tests).
Secondly, what I think was missed by the market was the battery test and the wording of the testing.
I have taken a deep dive into graph on the discharging cycle.
For simplicity lets say current leaders get a total charge of 300. ADO get 650. Now the graph shows discharging...."less than desirable" drops back to 600....still much greater than whats currently on the market. If the market clearly understood this then I believe the share price could be much higher.
